BRPI0507342A - sólidos supersaturados estabilizados de fármacos lipofìlicos - Google Patents

sólidos supersaturados estabilizados de fármacos lipofìlicos

Info

Publication number
BRPI0507342A
BRPI0507342A BRPI0507342-1A BRPI0507342A BRPI0507342A BR PI0507342 A BRPI0507342 A BR PI0507342A BR PI0507342 A BRPI0507342 A BR PI0507342A BR PI0507342 A BRPI0507342 A BR PI0507342A
Authority
BR
Brazil
Prior art keywords
lipophilic
drugs
solids
lipophilic drugs
stabilized
Prior art date
Application number
BRPI0507342-1A
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Schering Aktiengellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507342(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengellschaft filed Critical Schering Aktiengellschaft
Publication of BRPI0507342A publication Critical patent/BRPI0507342A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"SóLIDOS SUPERSATURADOS ESTABILIZADOS DE FáRMACOS LIPOFìLICOS". A presente invenção refere-se a uma composição famacêutica com dissolução melhorada de fármacos lipofílicos em um meio aquoso. Foi encontrado que aquelas composições farmacêuticas compreendendo um pó de compostos lipofílicos, tais como hormónios e esteróides (por exemplo, drospirenona e valerato de estradiol), na forma molecularmente dispersa, em conjunto com um veículo possuindo uma área superficial específica de pelo menos 250m¬ 2¬ /g, tal como dióxido de silica, por exemplo, o dióxido de silica vendido sob a marca registrada de Aeroperl<sym>, melhoraram suas propriedades de dissolução do fármaco de lipofílico.
BRPI0507342-1A 2004-03-10 2005-03-10 sólidos supersaturados estabilizados de fármacos lipofìlicos BRPI0507342A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
BRPI0507342A true BRPI0507342A (pt) 2007-07-03

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507342-1A BRPI0507342A (pt) 2004-03-10 2005-03-10 sólidos supersaturados estabilizados de fármacos lipofìlicos

Country Status (33)

Country Link
US (1) US8715735B2 (pt)
EP (2) EP2087883B1 (pt)
JP (1) JP5006185B2 (pt)
KR (1) KR101210695B1 (pt)
CN (1) CN1984644B (pt)
AR (1) AR048500A1 (pt)
AT (1) ATE442131T1 (pt)
AU (1) AU2005221403B8 (pt)
BR (1) BRPI0507342A (pt)
CA (1) CA2558582C (pt)
CR (1) CR8630A (pt)
DE (1) DE602005016551D1 (pt)
DK (1) DK1765290T3 (pt)
EA (1) EA012746B1 (pt)
EC (1) ECSP066902A (pt)
ES (2) ES2390406T3 (pt)
GT (1) GT200500045A (pt)
HK (1) HK1103660A1 (pt)
HR (1) HRP20090614T1 (pt)
IL (1) IL177894A0 (pt)
MY (1) MY142989A (pt)
NO (1) NO20064473L (pt)
NZ (1) NZ549793A (pt)
PA (1) PA8626101A1 (pt)
PE (1) PE20060016A1 (pt)
PL (1) PL1765290T3 (pt)
PT (1) PT1765290E (pt)
RS (1) RS51076B (pt)
SI (1) SI1765290T1 (pt)
SV (1) SV2005002044A (pt)
TW (1) TWI345986B (pt)
UY (1) UY28803A1 (pt)
WO (1) WO2005087199A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
CN101237851B (zh) * 2005-06-16 2013-09-18 沃纳奇尔科特有限责任公司 用于阴道给药的雌激素组合物
JP2009536165A (ja) * 2006-05-10 2009-10-08 エボニック デグサ ゲーエムベーハー 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用
LT2487162T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
ES2575549T3 (es) * 2007-04-11 2016-06-29 John A. Mccarty Comprimido de melatonina y métodos de preparación y uso
WO2009101021A2 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
CA2718255C (en) 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
EP2381946A4 (en) * 2008-10-10 2012-08-08 Teva Womens Health Inc METHOD FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN CASE RATED PROSTATE RAY PATIENTS WITH LOW-DOSED CYPROTERONE ACETATE
US20120064166A1 (en) * 2009-02-18 2012-03-15 Bayer Pharma Aktienesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CA2992923C (en) 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
WO2018149756A1 (en) * 2017-02-14 2018-08-23 Dsm Ip Assets B.V. Storage-stable formulations
EA201991799A1 (ru) * 2017-02-14 2019-12-30 ДСМ АйПи АССЕТС Б.В. Диспергируемые в воде составы
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
ES2062634T3 (es) 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
ATE118178T1 (de) * 1990-11-29 1995-02-15 Faulding F H & Co Ltd Verfahren zur herstellung von flüssigkeiten enthaltenden pulvern.
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
DK1598069T3 (da) 1999-08-31 2009-07-06 Bayer Schering Pharma Ag Farmaceutisk præparat af ethinylestradiol og drospirenon til anvendelse som præventionsmiddel
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
PL201878B1 (pl) 2000-01-18 2009-05-29 Bayer Schering Pharma Ag Kompozycja farmaceutyczna w doustnej postaci dawkowania. zawierająca estrogen i drospirenon, zastosowanie kompozycji i preparat farmaceutyczny
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
OA12625A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
ES2338782T3 (es) 2002-09-05 2010-05-12 Pantarhei Bioscience B.V. Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados.
PT1558265E (pt) 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
CA2516096A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
PT1748756E (pt) 2004-03-10 2009-07-20 Bayer Schering Pharma Ag Composições compreendendo drospirenona molecularmente dispersa

Also Published As

Publication number Publication date
ES2390406T3 (es) 2012-11-12
HK1103660A1 (en) 2007-12-28
CA2558582C (en) 2013-07-16
ECSP066902A (es) 2006-12-20
SV2005002044A (es) 2005-11-04
DE602005016551D1 (de) 2009-10-22
SI1765290T1 (sl) 2010-01-29
US20050207990A1 (en) 2005-09-22
CA2558582A1 (en) 2005-09-22
AR048500A1 (es) 2006-05-03
AU2005221403B2 (en) 2009-12-10
CN1984644A (zh) 2007-06-20
IL177894A0 (en) 2006-12-31
PA8626101A1 (es) 2006-07-03
EP1765290A2 (en) 2007-03-28
PT1765290E (pt) 2009-11-23
EP2087883B1 (en) 2012-07-25
CN1984644B (zh) 2010-12-08
NO20064473L (no) 2006-10-10
RS51076B (sr) 2010-10-31
AU2005221403B8 (en) 2010-01-07
GT200500045A (es) 2005-10-31
MY142989A (en) 2011-02-14
JP2007528389A (ja) 2007-10-11
WO2005087199A2 (en) 2005-09-22
PE20060016A1 (es) 2006-02-16
TW200600116A (en) 2006-01-01
EA200601588A1 (ru) 2007-02-27
PL1765290T3 (pl) 2010-02-26
EP1765290B1 (en) 2009-09-09
EP2087883A1 (en) 2009-08-12
UY28803A1 (es) 2005-10-31
NZ549793A (en) 2010-06-25
WO2005087199A8 (en) 2007-03-29
WO2005087199A3 (en) 2009-01-15
KR101210695B1 (ko) 2012-12-11
CR8630A (es) 2007-06-06
ATE442131T1 (de) 2009-09-15
JP5006185B2 (ja) 2012-08-22
EA012746B1 (ru) 2009-12-30
KR20060132999A (ko) 2006-12-22
ES2332229T3 (es) 2010-01-29
US8715735B2 (en) 2014-05-06
TWI345986B (en) 2011-08-01
HRP20090614T1 (hr) 2009-12-31
AU2005221403A1 (en) 2005-09-22
DK1765290T3 (da) 2009-11-02

Similar Documents

Publication Publication Date Title
BRPI0507342A (pt) sólidos supersaturados estabilizados de fármacos lipofìlicos
BR0211736A (pt) Formulação para suspensão oral estabilizada
IL178128A0 (en) Salts of 3-0-(3&#39;,3&#39;-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
ES2195308T3 (es) Composicon farmaceutica de fenofibrato que presenta una biodisponibilidad elevada, y metodo para su preparacion.
BRPI0717570B8 (pt) composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção
BR0107445A (pt) Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
EP1708719A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITIONS OF 2,6-DIISOPROPYLPHENOL (PROPOFOL) AND THEIR USE
DK1748756T3 (da) Præparater som omfatter drospirenon der er molekylært dispergeret
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BR9914932A (pt) Processo para a manufatura de uma composição de isotretinoìna, composição de isotretinoìna micronizada, forma de dosagem unitária para administração enteral e composição farmacêutica na forma de dosagem unitária
BR9910481A (pt) Composição farmacêutica para comprimido de liberação não-contìnua
BRPI0518191A (pt) métodos e composições para reduzir a toxicidade de um composto farmacêutico
BRPI0419048A (pt) composição útil para fornecer revestimento de remoção de nox sobre a superfìcie material
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0603197A (pt) composição de toner
ECSP055998A (es) Composición farmacéutica que comprende ácido 5-metil-2-2&#39;-(cloro-6&#39;-fluoroanilino)fenilacético
GT200500122A (es) Profarmacos de esteroides con accion androgenica
UY28910A1 (es) Prodrogas de estriol y estetrol
PE20070529A1 (es) Composicion farmaceutica que contiene azodicarbonamida micronizada y su preparacion
BR0116179A (pt) Composição despejável, processo de preparação de uma composição despejável e uso da composição
BRPI0518239A2 (pt) composiÇÕes farmacÊuticas espontaneamente dispersÍveis

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: NOME ALTERADO DE: SCHERING AKTIENGESELLSCHAFT

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE, CONFORME ART. 10 DA RES. 124/06.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.